Podcasts about falanga

➨ Iscrivetevi al nostro canale Telegram: https://t.me/spazio_70Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/spazio-70--4704678/support.Dalla costruzione del muro all'arrivo di Putin nella Germania Est. Intervista (gennaio 2023) a Gianluca Falanga. Studioso di storia contemporanea, Falanga vive e lavora a Berlino come libero ricercatore e consulente scientifico del Museo della Stasi. Tra le sue più recenti pubblicazioni: «Gli uomini di Himmler. Il passato nazista dei Servizi segreti tedeschi» (Carocci); «Non si parla mai dei crimini del comunismo» (Laterza); «La diplomazia oscura. Servizi segreti e terrorismo nella Guerra fredda» (Carocci); «Labirinto Stasi. Vite prigioniere negli archivi della Germania Est» (Feltrinelli).Tra gli argomenti toccati nell'intervista: 1) «Gli americani non avevano grandi reti informative proprie nella Germania orientale. Al contrario sostenevano la costruzione di reti informative da parte della Organizzazione Gehlen poi BND»; 2) «E' imminente la chiusura del confine». Il BND, poco prima della costruzione del muro, sapeva cosa si stava preparando; 3) «Brandt ha sempre negato di aver avuto informazioni precise su ciò che stava per avvenire»; 4) Un accordo tra Usa e Urss. L'ambasciatore sovietico prima del 13 agosto 1961 sulle misure che la DDR intendeva prendere; 5) Giugno 1961. L'assenso di Krusciov per la costruzione del muro; 6) «L'Ovest? Ha avuto una reazione rabbiosa»; 7) Il muro «visto» da Est e da Ovest; 8) «L'abbattimento non esisteva come opzione politica». L'appello di Reagan a Gorbaciov; 9) Il progetto «Muro 2000»; 10) Modalità per fuggire. I «tunnel» sotto il Muro; 11) Uno specifico reato nel codice penale DDR; 12) Non solo muro. Gli «altri» confini; 13) Il tema del riconoscimento internazionale della DDR e le ricadute mediatiche; 14) Unificazione o annessione? 15) L'arrivo di Putin nella DDR. Alcuni aspetti psicologici dell'uomo; 16) Il Kgb durante l'epoca brezneviana; 17) Perché Dresda? 18) «Dentro» la residentura di Putin; 19) Il lavoro di «coordinamento» nella collaborazione tra Stasi e Kgb; 20) L'individuazione di «profili» potenzialmente reclutabili; 21) Una sorta di «diritto di veto» della Stasi rispetto allo spionaggio sovietico; 22) Sulla figura di Lena S.; 23) Il mantenimento, da parte di Putin, dei rapporti con tutti i principali membri della residentura di Dresda;

Il ricercatore italiano Giulio Regeni è stato ucciso “tra le 22,00 del 31 gennaio e le 22,00 del 2 febbraio del 2016”. Le torture subite sono “provate e documentate” nonostante l'autopsia egiziana sia stata, forse volutamente, superficiale e incompleta. Per gli avvocati si tratterebbe di un'autopsia sotto gli standard minimi richiesti. Giulio Regeni è stato ucciso dopo le richieste di collaborazione all'Egitto formulate dall'ambasciatore italiano Maurizio Massari (il 25 gennaio 2016) e dall'ex presidente del consiglio Matteo Renzi e dall'allora ministro degli Esteri Paolo Gentiloni (31 gennaio 2016), che chiedevano al presidente egiziano Abdel Fattah al-Sisi notizie sul cittadino italiano scomparso. È stato torturato per sei giorni. “Sul corpo di Giulio Regeni – dicono i consulenti – sono state trovate quasi tutte le lesività elencate nella letteratura sulla tortura tipica in Egitto”. È un elenco dell'orrore. Torture ricorrenti, quelle elencate negli studi. Pugni, calci, mazze, percosse, bruciature, l'utilizzo di un “pettine chiodato” e la “Falanga”: le bastonate sui piedi che provocano la rottura di tutte le ossa, “riscontrata ahimè sul corpo di Giulio Regeni”, conferma il medico. La causa di morte comunicata dai medici egiziani, ovvero la “lesione cranica subdurale” è incompatibile con i risultati degli esami eggettuate dai periti. Questi sono gli elementi emersi ieri a Roma durante il processo ai quattro 007 egiziani. Queste sono le mani sporche di sangue del presidente egiziano al-Sisi che da anni insozzano stringendole quelle dei più importanti leader europei. Ogni accordo con l'Egitto ha questo colore, questo odore, questi frantumi. #LaSveglia per La NotiziaDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/la-sveglia-di-giulio-cavalli--3269492/support.

Professional Builders Secrets brings you an exclusive episode with Josh Hallam and Sam Falanga from Falanga & Co., an accounting firm based in Australia. In this episode, Josh and Sam get into the biggest pain points builders have when consulting with accountants, how to alleviate them, and most importantly, how to get the most out of your accountant. INSIDE EPISODE 128 YOU WILL DISCOVER The importance of an accountant who understands your business How builders differ from regular businesses What to look for in an accountant How builders should manage their cash flow ABOUT SAMUEL FALANGA Driven by a strong desire to help people build successful businesses, Sam established his own practice in 2011. Since founding Falanga & Co, Sam has built a highly capable team of business coaches, and has established the firm's reputation as a trusted and effective partner for success across multiple industries. Connect with Sam: linkedin.com/in/samuel-falanga-7939a265/ ABOUT JOSH HALLAM Bringing over a decade of senior executive experience to Falanga & Co, Josh is responsible for overseeing all aspects of the firm's operations. From the development and implementation of strategic plans, to ensuring the firm is meeting its financial and operational objectives, Josh plays a pivotal role in the strategic direction of the firm. Connect with Josh: linkedin.com/in/josh-hallam-6904711b/ TIMELINE 0:41 A bit about Falanga & Co. 3:35 Biggest accounting pain points for builders 8:00 How builders can manage their cash flow 12:05 Addressing common misconceptions about accountants 15:05 Falanga & Co.'s proactive approach 20:37 Changes throughout 2024 and beyond LINKS, RESOURCES & MORE APB Website: associationofprofessionalbuilders.com APB Rewards: associationofprofessionalbuilders.com/rewards/ APB on Instagram: instagram.com/apbbuilders/ APB on Facebook: facebook.com/associationofprofessionalbuilders APB on YouTube: youtube.com/c/associationofprofessionalbuilders

Les têtes d'affiche de Denise Epoté de TV5Monde, comme chaque dimanche sur RFI, aujourd'hui avec Nicolas Brousse. Sur la manchette, la Congolaise de RDC Clarisse Falanga, une biologiste moléculaire engagée, et l'ingénieur ivoirien Noël N'Guessa Kombo, ambassadeur de la Cleantech.

Dr. Nigel Key and Dr. Anna Falanga join us for a conversation on the updated ASCO VTE prophylaxis and treatment in patients with cancer guideline. They discuss recent evidence assessing apixaban for VTE treatment in patients with cancer and evaluating direct factor Xa inhibitors for extended postoperative prophylaxis. Based on this new evidence, they present updated evidence-based recommendations from the guideline expert panel. Dr. Key and Dr. Falanga also discuss outstanding questions regarding VTE prophylaxis and treatment in patients with cancer. Read the full guideline update, “Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Guideline Update” at www.asco.org/supportive-care-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/supportive-care-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest disclosures in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.23.00294.  Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one at ASCO.org/podcasts.  My name is Brittany Harvey, and today I'm interviewing Dr. Nigel Key from University of North Carolina, and Dr. Anna Falanga from University of Milan Bicocca, co-chairs on ‘Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Guideline Update'.  Thank you for being here, Dr. Key, and Dr. Falanga.  Dr. Nigel Key: Thank you.  Dr. Falanga: Thank you. Brittany Harvey: Then, before we discuss this guideline, I'd just like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including our guests on this episode, are available online with the publication of the guideline in the Journal of Clinical Oncology, linked in the show notes.  So then, jumping into this guideline update, Dr. Key, what prompted an update to the ‘ASCO VTE Guideline', which was last updated in 2019?  Dr. Nigel Key: Okay, well, thank you, Brittany, for that question. Well, first of all, ASCO has been providing this guideline since 2007 with iterations and full reviews of the data, the last complete one being in 2019. This update was really triggered by ASCO's signals approach, which relies on experts in the field suggesting an update to the guidelines based on recent publications that may be practice-changing. So, in this case, the signals were really a randomized control trial assessing apixaban for VTE treatment, venous thromboembolism treatment, in patients with cancer called the CARAVAGGIO trial, and we'll discuss that a little bit later. There were also a couple of randomized control trials which evaluated direct factor Xa inhibitors for extended postoperative prophylaxis, and these were new areas subsequent to the 2019 guidelines. So, a systematic review was carried out in the relevant topics for randomized control trials published between November 1, 2018, and June 6, 2022. And what you'll hear today is the result of that process.  Brittany Harvey: Great. And then you just described that guideline recommendations were updated both for prophylaxis and for treatment. So then, Dr. Falanga, what is the updated recommendation for perioperative VTE prophylaxis? Dr. Falanga: Thank you for this question. For this update, actually, there were two randomized trials addressing the extended thromboprophylaxis in cancer patients. This is an important question, and direct oral anticoagulants had never been included in the previous guidelines. So this new data indicating safety and in some way efficacy of these drugs were important to be in some way included. Actually, the two trials, one tested laparoscopic surgery in patients with colorectal cancer, so major surgery in colorectal cancer and tested the drug rivaroxaban against the placebo after one week of low molecular weight heparin. And the other trial tested in a different type of cancer, gynecological cancer surgery, apixaban versus a placebo after a short course with low molecular weight heparin.  So the two trials are very different, and the recommendation, after all, is weak. But the panel felt it was important to split the previous recommendation 3.5 into three recommendations. The 3.6 specifies which are the cancer patients that really need extended prophylaxis, or the recommendation addresses this population in particular at high risk, which means patients with laparoscopic or laparotomic abdominal pelvic surgery for cancer who have high risk characteristics, including restricted mobility, obesity, previous history of thrombosis, and other additional risk factors. So the recommendation is limited to this population. As I said, there is a weak recommendation because the two trials differ in the type of surgery, the type of the number of patients, the timing of prophylaxis, and one tested rivaroxaban and one tested apixaban. But in any case, the recommendation now reads that prophylaxis with these two direct oral anticoagulants may be offered in addition to the previous recommendation with the low molecular weight heparin for this indication, although the low molecular weight heparin indication remains a strong recommendation where these other two drugs are added. But still other research is needed to strengthen this recommendation. Brittany Harvey: Understood. Thank you for describing where there is evidence and where future research is needed to strengthen those recommendations and the qualifying statements for who is appropriate to receive this VTE prophylaxis. So then, Dr. Key, what did the expert panel update regarding treatment of patients with cancer with established VTE to prevent recurrence?  Dr. Nigel Key: Yes. First of all, I want to make it very clear that this particular recommendation deals, as you say, with patients with established venous thromboembolism. This is quite distinct from recommendations regarding primary prophylaxis in ambulatory patients, which is dealt with in a separate recommendation. That's number two in the 2019 guideline, and those have not been updated. But in terms of treatment of established venous thrombosis, there were three randomized control trials considered. They essentially all addressed the possible role of apixaban, which had not been included in the 2019 guideline. In this revised recommendation, the data looked at both the initial treatment of patients presenting with venous thrombosis as well as extended treatment, which what we know at present, really extends out to six months in terms of using non-vitamin K antagonists, preferably for extended prophylaxis.  So, in 4.1, the CARAVAGGIO trial that I mentioned earlier was a very large trial involving almost 1200 patients with cancer who had symptomatic or incidental acute proximal DVT or pulmonary embolism. And these patients were randomized to six months of treatment with either apixaban or dalteparin. And, in a nutshell, apixaban was non-inferior to dalteparin for the primary outcome of a recurrent VTE during the six month trial period. There was also a similar rate of major bleeding, 3.8 versus 4% in the two arms. So this was strong evidence that initial treatment could include apixaban in addition to what was already in the recommendations. And for those choosing to treat with heparin for initial five to ten days, as before, the recommendation is for low molecular heparin over unfractionated heparin.  So, the second part of this took into account the CARAVAGGIO trial, which I've already mentioned the result of, as well as two smaller trials. They had a VTE trial which had almost 300 patients, and again compared apixaban to dalteparin. And then there was a third smaller study comparing apixaban to lovenox in about 100 patients. But, essentially, the net outcome of the systematic review was that the recommendations 4.1 and 4.2 for, respectively, initial and extended treatment of established VTE, gave high quality evidence with a strong recommendation to include apixaban both for initial treatment and for extended treatment. Brittany Harvey: Understood. So then you've both discussed this a bit by describing the randomized trials supporting these recommendations. But Dr. Falanga, what should clinicians know as they implement these updated recommendations?  Dr. Anna Falanga: Well, clinicians should know that there are more options to offer to their patients for long-term treatment of VTE, as Dr. Key said, up to six months. This is an important expansion of the spectrum of choices for a more personalized treatment on the basis of the patient's characteristics and the drug characteristics. So this is very important to know. Also, for the postoperative prophylaxis, this update is relevant because of the recommendation. Although we are open to the perspective of using new drugs based on oral intake as an alternative to low molecular weight heparin, and knowing this drug appears to be safe in the specific setting where they were tested in the trial is important. Brittany Harvey: Definitely, it's great to have more options for patients. So then in your view, Dr. Key, how will these guideline recommendations impact patients with cancer?  Dr. Nigel Key: Well, I think that with more information that Dr. Falanga just presented, essentially we're looking at two different situations here, both the extended thrombosis prophylaxis after surgery and the choice of agent does need to be individualized with a discussion with a physician. There are still remaining concerns about increased bleeding with direct Xa inhibitors in patients with GI and GU malignancy, for example. So this needs to be taken into account, patients' creatinine values and so on, and what other drugs there are in terms of interactions with direct Xa inhibitors. So I think what you're looking at though is the ability to be confident for that patient that oral agents are, for the most part, as safe and effective as low molecular weight heparins. And hopefully, this will be something that is seen as a positive and maybe somewhat liberating effect for patients.  Brittany Harvey: That's great to hear.  So then finally, Dr. Falanga, you've already mentioned a few areas in which more research would be helpful to strengthen the recommendations. But are there other outstanding questions regarding VTE prophylaxis and treatment in patients with cancer?  Dr. Anna Falanga: Yes, there is a lot of work to be done ahead for prophylaxis. As we already mentioned, it's important to improve the evidence for direct oral anticoagulant safety and efficacy for extended, postoperative prophylaxis. In the medical setting, we have open questions about how to improve the management of patients with VTE beyond six months; we don't know for the treatment of VTE beyond six months, and identify better what are the best drugs and the best strategies to be utilized in this interval.  Then I think that we need to understand, in collaboration with cardiologists and neurologists, whether arterial thrombosis associated with the cancer may need a different treatment compared to subjects without cancer, and understand how to manage anticoagulant together with antiplatelet drugs in these patients who are often thrombocytopenic.  Finally, it is, of course, important to test new drugs for VTE treatment with potentially reduced bleeding risk, such as the new inhibitors of factor XI and factor XII. I think these are the major points that we need to address in the near future possibly.  Brittany Harvey: Absolutely. Well, we'll look forward to future updates of this ASCO guideline to discuss that research as it comes along.  So I want to thank you both so much for your work to update this guideline and thank you for your time today, Dr. Falanga and Dr. Key.  Dr. Anna Falanga: Thanks a lot. Bye bye.  Dr. Nigel Key: Thank you. You're very welcome. Bye bye.  Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/supportive-care-guidelines. You can also find many of our guidelines and interactive resources in the newly redesigned ASCO Guidelines app, available for free in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  

Hosts Julie Slater and Jason Friday chat with Michelle Falanga - Emmy-winning Voice Actor, published author, and overall manifester. We chat with Michelle about how she got into the voiceover world...her secret tricks to making it...how listening to her gut helped her...how she manifested that Emmy...some traumatic life events (1999 house fire, detached retina issues, health scare that lead to a 115 lb. weight loss)...how she likes STAYING PUT...her authentic self...and more. Follow @cuzihavetopodcast on Instagram for all the latest news. We'd love to hear from you - email us at cuzihavetopodcast@gmail.com. Find other episodes or leave us a voice message for the show on the anchor website. Thanks for tuning in! Keep on living those dreams, friends, CUZ YOU HAVE TO!! - jULIE AND jASON --- Send in a voice message: https://anchor.fm/cuzihaveto/message

Welcome back to the VTE Dublin Podcast where you'll find all the recent talks from the VTE Dublin Conference. Be sure to subscribe to the VTE Dublin Podcast Video: Audio:  

Registrazione della diretta You Tube e Twitch, del 24 giugno 2022, con Gianluca Falanga. Storico e ricercatore, da vent'anni attivo a Berlino presso il Museo della Stasi e l'ex carcere di Hohenschönhausen, Falanga ha svolto una rilevante attività di ricerca negli archivi di Stato tedeschi e pubblicato numerosi lavori sulla Stasi e la DDR. L'appuntamento sarà un'occasione per riscoprire un importante volume, intitolato appunto «Il Ministero della Paranoia. Storia della Stasi», pubblicato nel 2012, interamente dedicato al Ministero della Sicurezza dello Stato guidato per oltre trent'anni da Erich Mielke.

Ok, voyeurs, You Cheshire CATS… Here is your peek inside today's podcast…. Welcum to The Year of the Tiger 2022 A new year is always encompassed by setting New Years Resolutions. This year let's make sure we include Marital Resolutions! Like having sex with the lights on! In this podcast episode… We will talk about gaining control in your intimacy. A better bedroom perspective and getting rid of those hang-ups that keep your sex in the dark, literally! Speaking of subMrs,  our January theme is “Putting Best Foot Forward” in the new year. Our Mentor Chat topic is…. bastinado… Why?Because this month has INTERNATIONAL FETISH MONTH in it, we thought Falanga, or falaka or what it is known best as is bastinado, foot torture! This act is comprised of repetitive, blunt trauma to the soles of the feet. On subMrs we always mix pleasure with pain.. so we will explore foot torture and pleasure in “Foot/Toe” play. Marriage's Sexiest Secret 

371 p.n.e. – Zwycięstwo Teb nad Spartą w bitwie pod Leuktrami.1320 – Król Węgier Karol Robert poślubił królewnę polską Elżbietę Łokietkównę.1415 – Jan Hus został spalony na stosie podczas soboru w Konstancji.1439 – Zawarto Unię florencką.1511 – Albrecht Hohenzollern został wielkim mistrzem zakonu krzyżackiego.1785 – Dolar został przyjęty jako waluta narodowa Stanów Zjednoczonych.1885 – Pasteur przeprowadził pomyślny test szczepionki przeciwko wściekliźnie.1957 - Po raz pierwszy spotkali się John Lennon i Paul McCartney.

22 czerwca 168 p.n.e. – W bitwie pod Pydną Rzymianie pokonali Macedończyków.22 czerwca 1633 – Przed sądem Świętego Oficjum Galileusz wyparł się teorii kopernikańskiej.22 czerwca 1768 – Podczas konfederacji barskiej Krakus zabił Moskala guzkiem.22 czerwca 1792 – Król Stanisław August Poniatowski ustanowił Order Virtuti Militari.22 czerwca 1812 – Napoleon ogłosił początek II wojny polskiej.22 czerwca 1815 – Powtórna abdykacja cesarza Napoleona Bonapartego.22 czerwca 1905 – Wybuchło powstanie łódzkie.22 czerwca 1941 – rozpoczęła się operacja Barbarossa – niemiecki atak na ZSRR.22 czerwca 1944 – Armia Czerwona rozpoczęła ofensywę białoruską (operacja Bagration).22 czerwca 1986 – Maradona zdobył ręką bramkę w meczu między Argentyną a Anglią.https://www.spreaker.com/show/historia-dla-doroslychhttps://www.spreaker.com/show/historia-dla-dziecihttps://www.spreaker.com/show/historie-biblijne

ANNA FALANGA TORRE DEL GRECO

ANNA FALANGA TORRE DEL GRECO

Meet Emmy Award Winning Michelle Falanga, the voice actress that you'll be hearing voice the intros, outros, advertisements, and more for now on. Here, she talks about the new trend of authentic voice work and even coaches Chaz of Mr. Thrive Media on how to speak better behind the mic. ----------- HOST: Chaz Volk | Facebook Instagram Twitter - @MrThriveMeda | Chaz@MrThrive.com Guests: Michelle Falanga | www.michellefalanga.com Like the quality of this show? Thanks to Squadcast ===> https://squadcast.fm/?ref=charlesvolk ----------- This is a Mr. Thrive Media production | email: Chaz@MrThrive.com | Facebook, Instagram, and Twitter Learn more about your ad choices. Visit megaphone.fm/adchoices

Carmine Falanga volontario della cooperativa "Idee in fuga" ci presenta delle proposte per i regali natalizi e non solo, facendo una buona azione. Idee in Fuga è una Cooperativa Sociale attiva nell’Istituto Penitenziario “Cantiello e Gaeta” di Alessandria per creare lavoro per i detenuti.

Episode Notes In the spirit of listicles, Jordan joins in on the fun by sharing the most common medical misconceptions that she comes across. Get in, losers, we're practicing CPR. Sources: CDC. (2020, September 1). Misconceptions about flu vaccines. Centers for Disease Control and Prevention. https://www.cdc.gov/flu/prevent/misconceptions.htm Guillain-Barre syndrome—Symptoms and causes. (n.d.). Mayo Clinic. Retrieved from https://www.mayoclinic.org/diseases-conditions/guillain-barre-syndrome/symptoms-causes/syc-20362793 Helfman, T., Ovington, L., & Falanga, V. (1994). Occlusive dressings and wound healing. Clinics in Dermatology, 12(1), 121–127. https://doi.org/10.1016/0738-081X(94)90262-3 Protect yourself from superbugs. (n.d.). Mayo Clinic. Retrieved from https://www.mayoclinic.org/diseases-conditions/infectious-diseases/expert-answers/superbugs/faq-20129283 Weintraub, K. (2018, February 23). Can Being Cold Make You Sick? New York Times, 4. What is CPR. (n.d.). Cpr.Heart.Org. Retrieved from https://cpr.heart.org/en/resources/what-is-cpr Follow us on Instagram and Twitter @biopsychpod, and find us on Facebook too! Music by JayMan at https://bit.ly/2uWO2jO

Episódio #17 @LadoBdaCiencia1 Podcast Augusto Cesar F. De Moraes @ycare_rg & Francisco Leonardo Torres-Leal @torres_leal, conversaram com a Dr. Ariclecio Oliveira @ariclecio & Dra. Danielle Falanga @danielle_falanga sobre Obesidade, Inflamação Sistêmica Saúde Populacional e mortalidade COVID-19! Estamos em todos os agregadores! Compartilhe a palavra da ciência! #research #saúde #covid19 #covid #podcast #epitwitter #obesity #tratamento 
https://lado-b-da-ciencia-podcast.zencast.website/episodes/18 Topics discussed: ⇒ Recados (agradecer audiência; compartilhar com amigos, etc.). ⇒ Qual a relação entre obesidade e covid? ⇒ Existe maior risco um paciente morrer de Covid se ele for obeso? ⇒ Existe uma fisiopatologia atualmente clara da relação Covid e obesidade? ⇒ Todos obesos apresentam risco aumentado? ⇒ Conclusão: Dicas de conhecimento e/ou entretenimento. Dicas Culturais **Ariclecio: Livro: Andar do Bêbado: https://amzn.to/2JvtDtr **Dani: Serie: Dark: https://www.netflix.com/br/title/80100172 **Leonardo: Serie: Cosmos http://www.netflix.com/title/80004448 Augusto: Dear Brazil: “Neil deGrasse Tyson: https://www.haydenplanetarium.org/tyson/letters/2020-09-10-letter-to-brazil.php Música: Rape Me: Nirvana: https://www.youtube.com/watch?v=4TsqlT0rfJI PROTESTO contra violência contra mulher! **Livro: ATILA IAMARINO E SÔNIA LOPES - PRÉ-VENDA DO LIVRO: CORONAVÍRUS EXPLORANDO A PANDEMIA https://amzn.to/2TCb1tM Lado B da Ciencia Podcast - https://twitter.com/LadoBdaCiencia1 A ciência em nosso dia-a-dia -https://podcasts.apple.com/us/podcast/lado-b-da-ciencia-podcast/id1523585746 Sigam nossas redes sociais: Twitter: https://twitter.com/augustocesarfm Twitter: https://twitter.com/leotorresleal Twitter: https://twitter.com/YcareRG Instagram: https://www.instagram.com/ycare_rg/ Instagram: https://www.instagram.com/domen_rg/ This podcast is hosted by ZenCast.fm

A mini-episode with thanks and thoughts about one of the pioneers of magic publishing - Louis Falanga of L&L Publishing. Titles mentioned in this Episode llpub.com llepub.com Daryl does the Full Monte Jim Sisti Tribute https://forums.geniimagazine.com/viewtopic.php?f=10&t=52748

Alessandro è stato ospite della trasmissione COGITO ERGO SUM condotto da Walan e Gitù Mind e presenterà la sua opera d'esordio; ricordiamo che Alessandro è un giornalista e scrittore classe 85. Ideatore e curatore del sito web fighissimo Diario di Rorschach e collabora con diverse testate giornalistiche occupandosi di attualità, politica, eventi culturali, recensioni e per ultimo, e non meno importante, nostro collaboratore in Radio Scream Italia come redattore e speaker.

This week, a speedy, yet simple switch, and a video-based AI helps assess heart health.In this episode:01:57 Speedy switchesResearchers have developed an ultra-fast electrical switch that they hope can be used in communication and imaging applications. Research Article: Nikoo et al.08:14 Research HighlightsUsing sound to estimate glacial retreat, and building a dodgier drone. Research Highlight: Underwater microphones listen as as glacier retreats; Research article: Falanga et al.10:32 Algorithmic heart diagnosisScientists have developed a new algorithm which calculates the amount of blood pumped by the heart beat by beat. Research Article: Ouyang et al.; News and Views: AI tracks a beating heart’s function over timeSubscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. See acast.com/privacy for privacy and opt-out information.

Agile testing has developed exponentially over the last two decades, with the role of QA continuously transforming. In this episode, Jonathon Wright with Kate Falanga, Associate Director of QA at Code & Theory, to discuss the evolution of the QA role in Agile.  

Agile testing has developed exponentially over the last two decades, with the role of QA continuously transforming. In this episode, I'm joined with Kate Falanga, Associate Director of QA at Code & Theory, to discuss the evolution of the QA role in Agile.

An interview with Dr. Anna Falanga on "Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guideline Update." The guideline revises several previous recommendations. Most notably, direct oral anticoagulants (DOACs) have been added as options for VTE prophylaxis and treatment. Read the full guideline at www.asco.org/supportive-care-guidelines Find all of ASCO's podcasts at podcast.asco.org  TRANSCRIPT Hi, my name is Clifford Hudis and I am the CEO of ASCO and the host of the ASCO in Action Podcast. About twice a month, I interview thought leaders in health care and experts in oncology, and we provide analysis and commentary on a wide range of cancer policy and practice issues.   You can find the ASCO in Action Podcast on Apple Podcasts or wherever you are listening to this show, and you can find all 9 of ASCO’s podcasts which cover a wide range of educational and scientific content and offer enriching insight into the world of cancer care at podcast.asco.org Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care, and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Hello and welcome to the ASCO Guidelines Podcast series. My name is Shannon McKernin. And today I'm interviewing Dr. Anna Falanga from the hospital Papa Giovanni XXIII in Bergamo, Italy. Senior author on "Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guidelines Update." Thank you for being here today, Dr. Falanga. Yes, thank you. I am very happy to talk on the update of the ASCO VTE guidelines. So this guideline was first published in 2007 with an update in 2013 and a reaffirmation in 2015. So what prompted this 2019 update? Thanks for this first question. I think that an update was urgently needed at this time. You know, before, the ASCO guidelines were published in 2007. And then an update was made in 2013, and the second one in 2015. But in 2015 was basically a confirmation of the previous 2013 update. Now the update was urgently needed, because in the very recent years there has been even more evidence of the relevance and impact of a venous thromboembolism in the cancer patients. But in addition, and very importantly, new data from prospective randomized clinical trials with the new drugs for the management of VT in the oncological patients have become available. In particular, as you know, low molecular weight heparins were largely used in the setting of the treatment and trauma prophylaxis in the cancer patients. And actually, the low molecular weight tapering have been the standard of treatment for many years. However, recently the results of prospective randomized clinical trials of direct oral anticoagulant, particularly, the anti-Xa inhibitors, Edoxaban and Rivaroxaban, for cancer associated with [INAUDIBLE] treatment support the role of this new oral agent in the VT management in this setting. And this is related to new politics in the VT management in these patients. So what are the key recommendations for this guideline update? The main changes to the previous recommendations are first that Rivaroxaban and Edoxiban, the two anti-Xa inhibitors oral anticoagulants have been added as an option for routine treatment in cancer patients in this update. Also, now we may offer thrombo prophylaxis with Apixaban, Rivaroxaban, or low molecular weight tapering to selected high-risk outpatients with cancer. And about other changes of these new guidelines compared to the last one include that patients with brain metastases have been addressed in the VT type treatment sections, whereas before, only patients with the primary tumors were mentioned in the previous edition. And finally, the recommendation regarding long-term postoperative thromboprophylaxis with low molecular weight heparin expanded to patients undergoing a major open or laparoscopic abdominal or pelvic surgery. These are the main changes that all I think are very, very important. Why is this guideline so important? And how does it affect practice? Well, I think that the question how these changes affect our practice is a very important question, because I believe that these guidelines reflect the new evidence that we have from the new data. And this data clearly expand our possibility to choose now between the different treatment options in the single patient in the cancer population. For instance, the new data show that treatment with [INAUDIBLE] anticoagulants compared to low molecular weight heparin lower the risk of a recurrent thrombosis. But in some instances there's a higher risk of bleeding, particularly in the gastrointestinal and urinary tract cancer patients. So therefore it is evident that the patient selection and the individualization of a therapy based on the patient characteristics and the type of cancer-- all these become very important. And we have the possibility now to choose between different treatments, or in the same patients we can change from one treatment to the other according to the face of the disease or complications if the patient is in a phase that is assuming chemotherapy with many side effects like nausea and vomiting. Of course, in these cases a parenteral injection is preferable for the management of a venous thromboembolism. Whereas in other instances, a long-term and oral intake is surely more convenient. So it depends also from the level of risk. But now for the six months treatment we can offer different choice of the oral treatment and also for high-risk patients the primary prophylaxis with Apixaban Rivaroxoaban, and a low molecular weight tapering can be chosen. And what should patients be aware of when it comes to VTE risks and treatments? I think that patients should be educated about the risk of a cancer associated with VTE. You know, there is that evidence that they are educated about it. And they know a lot better about neutropenia, and the fever associated with this the neutropenic condition and the other side effect. But they know very little about the possibility that they can experience venous thromboembolism.  So I think they should be taught on how to recognize the symptoms and alert their physician. You know, sometimes the symptoms are indistinguishable It can be just a little pain in the calf. And patients must know that these are to be considered important. They must alert their physician to undergo some test-- objective test-- to see if there is a real thrombosis in the leg or not. This is extremely important, because one important consequence of venous thromboembolism of the extremities is a pulmonary embolism that can be also fatal. So they must know about that. Also, I think they should know about the risk of bleeding associated with the anticoagulant treatment, and also that this risk of bleeding can be different in the different type of tumors. Finally, I think that also they must be told about the once they have, for instance, and episode of venous thromboembolism they have to receive a treatment for that, and these are usually six months to the minimum, and then we'll decide. So they must know what these are the efficacy and the safety profiles of the different drugs. They must know the differences in the route of administration and the other characteristics of the drug. So I think that their shared decision with the patients of the type of treatment must be an integral part of the decision making and is certainly desirable. Great. It sounds as though there's some important considerations for patients and important conversations which may be prompted by this guideline. So thank you for taking your time to discuss this with me today, Dr. Falanga. I thank you very much for this interview and talk that our colleagues and also the patients will be happy with these new guidelines of ASCO. Thank you. And thank you to all of our listeners for tuning into the ASCO Guidelines Podcast series. To read the full guideline, go to www.asco.org/supportive-care-guidelines. And if you've enjoyed what you've heard today, please rate and review the podcast and refer the show to a colleague.

Compre livros com desconto aqui https://amzn.to/2BHsh7d Frank Frazetta (9 de fevereiro 1928 – 10 maio 2010) é, provavelmente o ilustrador e pintor norte-americano mais cultuado da sua geração. Frazetta é um pintor figurativo que trabalhou com um estilo realista que trabalhava principalmente uma temática fantástica medieval. Frazetta ficou famoso por suas mulheres exuberantes, suas criaturas ferozes e um trabalho impressionante com a anatomia de corpos sempre perfeitos e musculosos. Mas isso é uma visão bem superficial, na verdade. O domínio dele de contraste e intensidade de cores (além das escolhas de áreas de maior e menor definição) e uma entendimento global do design da imagem, se preocupando com a criação de planos, profundidade, movimento, dramaticidade e narrativa era o que de fato torna o trabalho dele tão atraente. Como todo ícone ele é envolto em mitos e lendas, uma das mais curiosas é que dizem que ele alegava ter aprendido anatomia em uma noite copiando todo o livro do Bridgman (https://amzn.to/2HclEO5), mas, na verdade, ele estudou desde os 8 anos na Academia de Belas Artes do Brooklyn onde foi aluno de um artista italiano chamado Michele Falanga, que acreditava tanto no jovem Frazetta que queria mandá-lo estudar na Europa, mas Falanga faleceu antes e Frazetta teve que buscar um trabalho comercial e seguiu para os quadrinhos. A linha de trabalho do Frazetta foi enveredando para a fantasia e, mesmo recebendo ofertas de gigantes como a Disney, ele optou por seguir nessa linha em publicações como a da EC Comics. No vídeo, além de mostrar algumas obras, eu fiz uma pequena análise de algumas das técnicas que valem ser estudadas na obra desse artista. Compre livros de Frank Frazetta aqui https://amzn.to/31FONsE Siga o instagram @frazettagirls https://youtu.be/lGA2nvOQ9_Y (adsbygoogle = window.adsbygoogle || []).push({});

An interview with Dr. Anna Falanga on "Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guideline Update." The guideline revises several previous recommendations. Most notably, direct oral anticoagulants (DOACs) have been added as options for VTE prophylaxis and treatment. Read the full guideline at www.asco.org/supportive-care-guidelines Find all of ASCO's podcasts at podcast.asco.org  TRANSCRIPT Hi, my name is Clifford Hudis and I am the CEO of ASCO and the host of the ASCO in Action Podcast. About twice a month, I interview thought leaders in health care and experts in oncology, and we provide analysis and commentary on a wide range of cancer policy and practice issues.   You can find the ASCO in Action Podcast on Apple Podcasts or wherever you are listening to this show, and you can find all 9 of ASCO’s podcasts which cover a wide range of educational and scientific content and offer enriching insight into the world of cancer care at podcast.asco.org Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care, and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Hello and welcome to the ASCO Guidelines Podcast series. My name is Shannon McKernin. And today I'm interviewing Dr. Anna Falanga from the hospital Papa Giovanni XXIII in Bergamo, Italy. Senior author on "Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guidelines Update." Thank you for being here today, Dr. Falanga. Yes, thank you. I am very happy to talk on the update of the ASCO VTE guidelines. So this guideline was first published in 2007 with an update in 2013 and a reaffirmation in 2015. So what prompted this 2019 update? Thanks for this first question. I think that an update was urgently needed at this time. You know, before, the ASCO guidelines were published in 2007. And then an update was made in 2013, and the second one in 2015. But in 2015 was basically a confirmation of the previous 2013 update. Now the update was urgently needed, because in the very recent years there has been even more evidence of the relevance and impact of a venous thromboembolism in the cancer patients. But in addition, and very importantly, new data from prospective randomized clinical trials with the new drugs for the management of VT in the oncological patients have become available. In particular, as you know, low molecular weight heparins were largely used in the setting of the treatment and trauma prophylaxis in the cancer patients. And actually, the low molecular weight tapering have been the standard of treatment for many years. However, recently the results of prospective randomized clinical trials of direct oral anticoagulant, particularly, the anti-Xa inhibitors, Edoxaban and Rivaroxaban, for cancer associated with [INAUDIBLE] treatment support the role of this new oral agent in the VT management in this setting. And this is related to new politics in the VT management in these patients. So what are the key recommendations for this guideline update? The main changes to the previous recommendations are first that Rivaroxaban and Edoxiban, the two anti-Xa inhibitors oral anticoagulants have been added as an option for routine treatment in cancer patients in this update. Also, now we may offer thrombo prophylaxis with Apixaban, Rivaroxaban, or low molecular weight tapering to selected high-risk outpatients with cancer. And about other changes of these new guidelines compared to the last one include that patients with brain metastases have been addressed in the VT type treatment sections, whereas before, only patients with the primary tumors were mentioned in the previous edition. And finally, the recommendation regarding long-term postoperative thromboprophylaxis with low molecular weight heparin expanded to patients undergoing a major open or laparoscopic abdominal or pelvic surgery. These are the main changes that all I think are very, very important. Why is this guideline so important? And how does it affect practice? Well, I think that the question how these changes affect our practice is a very important question, because I believe that these guidelines reflect the new evidence that we have from the new data. And this data clearly expand our possibility to choose now between the different treatment options in the single patient in the cancer population. For instance, the new data show that treatment with [INAUDIBLE] anticoagulants compared to low molecular weight heparin lower the risk of a recurrent thrombosis. But in some instances there's a higher risk of bleeding, particularly in the gastrointestinal and urinary tract cancer patients. So therefore it is evident that the patient selection and the individualization of a therapy based on the patient characteristics and the type of cancer-- all these become very important. And we have the possibility now to choose between different treatments, or in the same patients we can change from one treatment to the other according to the face of the disease or complications if the patient is in a phase that is assuming chemotherapy with many side effects like nausea and vomiting. Of course, in these cases a parenteral injection is preferable for the management of a venous thromboembolism. Whereas in other instances, a long-term and oral intake is surely more convenient. So it depends also from the level of risk. But now for the six months treatment we can offer different choice of the oral treatment and also for high-risk patients the primary prophylaxis with Apixaban Rivaroxoaban, and a low molecular weight tapering can be chosen. And what should patients be aware of when it comes to VTE risks and treatments? I think that patients should be educated about the risk of a cancer associated with VTE. You know, there is that evidence that they are educated about it. And they know a lot better about neutropenia, and the fever associated with this the neutropenic condition and the other side effect. But they know very little about the possibility that they can experience venous thromboembolism. s So I think they should be taught on how to recognize the symptoms and alert their physician. You know, sometimes the symptoms are indistinguishable It can be just a little pain in the calf. And patients must know that these are to be considered important. They must alert their physician to undergo some test-- objective test-- to see if there is a real thrombosis in the leg or not. This is extremely important, because one important consequence of venous thromboembolism of the extremities is a pulmonary embolism that can be also fatal. So they must know about that. Also, I think they should know about the risk of bleeding associated with the anticoagulant treatment, and also that this risk of bleeding can be different in the different type of tumors. Finally, I think that also they must be told about the once they have, for instance, and episode of venous thromboembolism they have to receive a treatment for that, and these are usually six months to the minimum, and then we'll decide. So they must know what these are the efficacy and the safety profiles of the different drugs. They must know the differences in the route of administration and the other characteristics of the drug. So I think that their shared decision with the patients of the type of treatment must be an integral part of the decision making and is certainly desirable. Great. It sounds as though there's some important considerations for patients and important conversations which may be prompted by this guideline. So thank you for taking your time to discuss this with me today, Dr. Falanga. I thank you very much for this interview and talk that our colleagues and also the patients will be happy with these new guidelines of ASCO. Thank you. And thank you to all of our listeners for tuning into the ASCO Guidelines Podcast series. To read the full guideline, go to www.asco.org/supportive-care-guidelines. And if you've enjoyed what you've heard today, please rate and review the podcast and refer the show to a colleague.

Ne parliamo con l’Avv. Piero Ralleva, Presidente Commissione Elettorale CoA Taranto. “La norma sul doppio mandato è sacrosanta, ma la legge Falanga non ci da il potere di escludere gli ineleggibili”.Intervista a cura di Pierluigi Serra

Ne parliamo con l’Avv. Francesco Greco, con i commenti dell’Avv. Domenico Monterisi e dell’Avv. Elia Barbujani “Caso Falanga, fra smentite e retromarce”.Intervista a cura di Domenico Monterisi ed Elia Barbujani

Ne parliamo con l'avv. Ciro Falanga, già Deputato e SenatoreIntervista a cura di Domenico Monterisi

Ne parliamo con l’Avv. Roberto Marra, del Foro di Lecce e Presidente Commissione Elettorale CoA Lecce “La legge Falanga non attribuisce alle Commissioni il potere di escludere i candidati con un doppio mandato alle spalle”.Intervista a cura di Pierluigi Serra

Torna il talk show dell’Avvocatura per un aggiornamento sugli effetti della sentenza delle Sezioni Unite sulle elezioni forensi. Molti i colleghi plurimandatari candidati, iniziano a riunirsi le commissioni elettorali.Chiama in diretta al 3313097852.Ne parleremo con:Giovanni Delucca, Presidente ANFPaolo Rossi, Presidente AIGA Bologna e componente Giunta AIGA NazionaleArgia di DonatoMarco Micciché, Direttore IusLaw WebRadio.Con l’intervento di Mirella Casiello.Conducono: Milena Miranda e Elia BarbujaniRegia: Ornella Sala.

Italy's Desserts, Francine Segan Smithsonian Associates, Interview Series Forget about milk and cookies: Italians love to end their meal with cookies and special dessert wines. Join Francine Segan, author of Dolci: Italy's Sweets, as she introduces you to la dolce vita—the way the dessert course is enjoyed in Italy.  Dig into the tradition of sublime pastries and such as cannoli, gelato, rum baba, biscotti, amaretti, granita, marzipan, and more. Discover the sweet advantage Italy had over the rest of Europe in developing dessert as Segan traces the fascinating stories behind of delicious sweets like black rice, “virgin's breasts,” and a sweet pudding called “pope's soup.” Learn about special carnival-season, Easter, and Christmas desserts and the many influences Italy has had on America's classic desserts. Enjoy a reception with award-winning Italian treats graciously donated by companies including chocolatiers Bonajuto, Falanga, and Venchi, and San Patrignano bakers. Check out our web site for tickets and more information: https://notold-better.com

Speciale - ATUXTUGli speciali di IuslawwebradioATUXTU - Questa sera ore 21.30Parliamo della Legge Falanga e delle nuove regole per le Elezioni Forensi con:Antonio Rosa, Mauro Vaglio, Giovanni Stefanì, Cosimo D. Matteuccii, Andrea Bertollini ed Ester Perifano.Conducono Pino Gallo e Pierluigi Serra con Domenico Monterisi.Regia di Adelperio de Negri di San PietroSegui la diretta su: www.webradioiuslaw.it/direttaRingraziamo gli artisti amici ed ospiti: - Mash - Karrin Allyson - Giuseppe Pucciarelli - Peter Erksine******************************

Scarica il programma

Il treno della discordia. Provocazioni tra Serbia e Kosovo. Stefano Giantin, giornalista - La corte tedesca si è pronunciata sul partito neonazista. Gianluca Falanga, storico ed esperto di Germania.

Il siriano arrestato in Germania grazie a due suoi connazionali. Prof. Gianluca Falanga, storico - Senza tetto a Torino. Corrado Franco, regista.

Adriano Zumbo, host of the new Seven reality cooking competition show Zumbo's Just Desserts is joined by his on-screen assistant Gigi Falanga in his conversation with Mediaweek editor James Manning and deputy editor Dan Barrett. In addition to telling us about the new show, Zumbo discusses his TV downtime between Masterchef and the new show. He also offers his thoughts on Willy Wonka, the challenges of running his retail business, and the rise of the freakshake.

"Tools should be secondary to what you're trying to achieve with BDD and the value that it brings," says Kate Falanga, Director of QA at Huge, of some people's fascination with BDD tools. Kate's session at Agile Alliance Technical Conference 2016 was a workshop called "Behavior-Driven Development for Non-Coders" and aimed to promote "shift left" testing: starting testing earlier in the development cycle (toward the left, if you're looking at the dev workflow). Part of Kate's workshop centered around acting out a story kickoff session with "a really terrible user story that I wrote." The goal was to focus on communication and for participants to feel how it changed the user story. The story kickoff session or huddle serves to clearly identify the requirements in a user story before any development takes place and as a result the best huddle with have the developer, the tester and the Product Owner. This ensures that any low-hanging fruit (both problems and opportunities) are addressed at the development stage, rather than later when changes are much more expensive. If you're gonna invite someone else into the huddle (or "Three Amigos" as some cheekily call it), Kate says consider a visual UX or design expert. Kate Falanga (Director, Quality Assurance at Huge) has over 14 years of digital experience. At Huge she works with a full time team of quality assurance professionals as well as actively supports projects and project teams with testing mentorship. As part of her role she works alongside other leadership within the company on overall technical strategy. SolutionsIQ's Leslie Morse hosts. About Agile Amped The Agile Amped podcast series engages with industry thought leaders at Agile events across the country to bring valuable content to subscribers anytime, anywhere. To receive real-time updates, subscribe at YouTube, iTunes or SolutionsIQ.com. Subscribe: http://bit.ly/SIQYouTube, http://bit.ly/SIQiTunes, http://www.solutionsiq.com/agile-amped/ Follow: http://bit.ly/SIQTwitter Like: http://bit.ly/SIQFacebook

El pianista Marco Mezquida presenta "Cantabile", segundo trabajo de su trío con Marko Lohikari (cb) y Carlos Falanga (bt), en el que cuentan como invitado con el saxofonista Bill McHenry, de quien, en esta edición de 'Club de Jazz' del 26 de diciembre de 2015, escuchamos también su participación en el proyecto US Free junto a Henry Moore (cb) y Andrew Cyrille (bt). Aprovechamos para picotear también en el contenido del "Gran Coral" de Falanga y en "Ocean Blood", trabajo del saxofonista Miguel Fernández en el que participa Mezquida. El baterista gallego Iago Fernández nos sosiega con "Acougo", trabajo en sexteto, mientras el guitarrista astuariano Carlos Pizarro acuna "El sueño de las flores", disco en el que recuerda al fallecido pianista navarro Mauro Urriza. Toda la información y derechos: http://www.elclubdejazz.com

El pianista Marco Mezquida presenta "Cantabile", segundo trabajo de su trío con Marko Lohikari (cb) y Carlos Falanga (bt), en el que cuentan como invitado con el saxofonista Bill McHenry, de quien, en esta edición de 'Club de Jazz' del 26 de diciembre de 2015, escuchamos también su participación en el proyecto US Free junto a Henry Moore (cb) y Andrew Cyrille (bt). Aprovechamos para picotear también en el contenido del "Gran Coral" de Falanga y en "Ocean Blood", trabajo del saxofonista Miguel Fernández en el que participa Mezquida. El baterista gallego Iago Fernández nos sosiega con "Acougo", trabajo en sexteto, mientras el guitarrista astuariano Carlos Pizarro acuna "El sueño de las flores", disco en el que recuerda al fallecido pianista navarro Mauro Urriza. Toda la información y derechos: http://www.elclubdejazz.com

This is our conversation with Damiano Falanga, our good friend from high school.  He is a fellow nerd and witty person, which makes him a perfect match for us!  Enjoy!  He's @madaxion on twitter!